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Abstract
Introduction and Aims. Cognitive impairments in substance use disorder predict treatment outcome and are assumed to
differ between substances. They often go undetected, thus the current study focuses on the prevalence of and differences in cogni-
tive functioning across substances by means of a cognitive screen at the early stage of addiction treatment. Design and
Methods. The Montreal Cognitive Assessment was administered to outpatients seeking treatment for substance use disorder.
Patient characteristics (age, years of regular use, polysubstance use, severity of dependence/abuse, depression, anxiety and
stress) were also taken into account. Results. A total of 656 patients were included (n = 391 used alcohol, n = 123 used
cannabis, n = 100 used stimulants and n = 26 used opioids). The prevalence of cognitive impairments was 31%. Patients
using alcohol had a lower total- and memory domain score than those using cannabis. Patients using opioids scored lower on
visuospatial abilities than those using cannabis or stimulants. Younger patients scored higher than older patients. No effect
was found for the other investigated characteristics. Discussion and Conclusions. Given the high prevalence of cognitive
impairments, standard screening at an early stage of treatment is important to determine the course of treatment and maximise
treatment outcome. Caution is needed in interpreting results about opioids due to an underrepresentation of this patient group,
and more research is needed on the effect of age on Montreal Cognitive Assessment performance. [Bruijnen CJWH, Dijkstra
BAG, Walvoort SJW, Markus W, VanDerNagel JEL, Kessels RPC, De Jong CAJ. Prevalence of cognitive impair-
ment in patients with substance use disorder. Drug Alcohol Rev 2019;38:435–442]
Key words: substance use disorder, cognitive impairment, Montreal cognitive assessment, prevalence.
Introduction
Substance use disorder (SUD) refers to ‘a cluster of
cognitive, behavioural and physiological symptoms
indicating that the individual continues using the sub-
stance despite signiﬁcant substance-related problems’
(p. 483) [1]. Substances like alcohol, cannabis, stimu-
lants and opioids are psychoactive drugs that may
change brain function and structure after chronic use,
and result in cognitive and behavioural deﬁcits that
remain even after detoxiﬁcation. The prevalence of
cognitive impairments in patients with SUD is still
unclear [2] and is estimated between 30% and 80%
[3]. This wide range includes, for instance, differences
in the mode of action between substances, years and
amount of regular use, and effects of gender. As each
substance has different effects on brain functioning the
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consequences of prolonged substance use, such as cog-
nitive impairments, will also differ between substances.
Acute alcohol intoxication primarily acts upon cog-
nitive functions associated with the prefrontal cortex,
such as planning, verbal ﬂuency, memory and complex
motor control [4,5]. The effects of alcohol on cognitive
functioning post-detoxiﬁcation are found to affect all
cognitive domains [6]. After 1 to 3 weeks of absti-
nence, chronic alcohol use is still associated with
decrements in memory, visuospatial abilities and inhi-
bition [7]. After six months of abstinence, cognitive
recovery generally has occurred [8] but impairments
have still been demonstrated in the domains of visuo-
spatial abilities and decision making [9] which may last
at least up to 1 year after abstinence [6,7]. There is
some evidence that in the long term, the cognitive con-
sequences of alcohol use disorder (AUD) may be fully
reversible [10], but cases of persistent cognitive
impairments like Korsakoff’s syndrome are not
uncommon [11].
The acute consequences of cannabis intoxication
primarily involve working memory, executive function-
ing and attention [12]. Post-detoxiﬁcation effects have
been found to impact executive functioning after 17 h
until up to 21 days of abstinence [13–15]. In the long
term (i.e. after more than one month of abstinence),
full cognitive recovery can occur [7,14,16].
Concerning stimulant abuse, including cocaine,
amphetamine and ecstasy, cognitive impairments are
considered relatively mild [17] and seem to follow
an inverted U-shape [18]. Acute intoxication with
low doses has mostly enhancing effects on response
inhibition, attentiveness, speed and psychomotor
performance [19,20]. Cognitive impairments that
occur after short-term abstinence in executive func-
tioning, inhibition, (verbal) memory, psychomotor
functions and attention disappear again after long-
term remission [7,19–24]. After 1 year of complete
abstinence cognitive function has been found to be
at the level of healthy controls [25,26]. There are
case studies, however, that report major cognitive
impairments in patients with a history of chronic
stimulant use, with dosage being the critical determi-
nant [18,20,27].
Regarding opioid abuse, relatively few studies have
assessed the acute cognitive sequelae. There is, how-
ever, ample evidence of impairments in the memory
domain [28], and impairments are also found after
short-term abstinence in executive functioning, such as
verbal ﬂuency, inhibition and decision-making. These
impairments have been demonstrated after up to 1 year
of abstinence [7]. Whether full recovery occurs is
largely unknown, although it has been found that at
least some recovery is possible after long term absti-
nence of opioid abuse [29].
Cognitive deﬁcits in chronic substance abuse are
clinically relevant, as they affect treatment outcome and
predict dropout rates as compared to cognitively intact
users [30]. In AUD, cognitive impairments are associ-
ated with worse treatment compliance and lower self-
efﬁcacy, which in turn result in a drinking outcome
with fewer abstinent days and more drinks per drinking
day [31,32]. Poorer treatment outcomes, lower treat-
ment retention and less abstinence are also found in
cocaine users with mild cognitive impairments [33,34].
Poor executive function performance is associated with
worse recognition of problem use and hampers the
intention to stop using in both opioid and cocaine users
[35,36]. Interventions targeting cognitive functioning,
or taking cognitive impairments into account, may lead
to a better treatment outcome both regarding the addic-
tion and in everyday functioning [37,38].
Although the literature carefully suggests that full
recovery of cognitive impairments may be possible for
all substances, the inﬂuence of cognitive impairments
on treatment outcome shows the importance of detect-
ing these impairments for each individual at an early
stage, so that personalised treatment can be implemen-
ted. The current study focuses on the prevalence of
cognitive impairments and differences in cognitive
functioning across substances by means of a cognitive
screen [the Montreal Cognitive Assessment (MoCA;
39)] at the early stage of addiction treatment right
before interventions are being initiated. The ﬁrst aim is
to determine, at intake, the prevalence of cognitive
impairments in patients using different substances. Dif-
ferences in cognitive performance across substances
will be studied per cognitive domain. The second aim
is to investigate the effects of age, abstinence (i.e. not
having used prior to MoCA assessment classiﬁed as
<7 days, 7–41 days or ≥ 42 days), abstinence duration
(i.e. number of days abstinent prior to MoCA assess-
ment, with a minimum of 7 days), polysubstance use,
duration of regular use, severity of dependence/abuse,
depression, anxiety and stress on cognitive functioning.
Methods
Design
A cross-sectional study was performed in which a
validated cognitive screening instrument was adminis-
tered as part of the intake procedure that contains items
covering all cognitive domains, the MoCA [39].
Data were collected between April 2012 and December
2014 in four addiction treatment centres. The study
was approved by the internal review boards of all
participating health-care centres and the research board
of the Nijmegen Institute for Scientist-Practitioners in
Addiction.
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Participants
The aim was to include a total of 800 participants seek-
ing treatment for SUD in one of four addiction care
centres in the Netherlands (IrisZorg, Novadic-Kentron,
Tactus and Vincent van Gogh Institute for Psychiatry).
The inclusion criteria were: (i) dependency or abuse of
a substance (excluding nicotine) or behaviour; (ii) age
18–75; and (iii) signed informed consent for participa-
tion. The only exclusion criterion was an inability to
administer the MoCA, due to for instance a neurologi-
cal (e.g. stroke, dementia, traumatic brain injury) or
very instable acute psychiatric disorder, severe lack of
motivation or insufﬁcient Dutch language skills.
Patients were included regardless of substance use sta-
tus to comply as much as possible with treatment as
usual in all participating institutions and to maximize
the generalisability of the sample in relation to the pop-
ulation that is referred to addiction clinics in general.
Materials
Measurements in the addictions for triage and evaluation.
The Measurements in the Addictions for Triage and
Evaluation (MATE 2.1) [40] consists of an interview
and self-report questionnaires for collecting informa-
tion relevant for treatment purposes. In this study four
sections were used. Section 1 ‘Substance use’, is an
interview that assesses the use of nine psychoactive
substances and behavioural addictions in the past
30 days as well as lifetime. The primary-problem sub-
stance is determined by both the patient and the asses-
sor as the substance that causes the most problems.
For the current study, a participant was considered a
polysubstance user if any substance other than the
primary-problem substance, had a lifetime use of 1 year
or longer, excluding nicotine and behavioural addic-
tions. Section 3 ‘History of treatment for substance
use disorders’, assesses if a patient has ever been in
treatment for addiction. Section 4 ‘Substance depen-
dence and abuse’, Section Alcohol & Drugs of the
Composite International Diagnostic Interview [41], is
an interview questionnaire that helps to diagnose sub-
stance abuse or dependence by answering 11 yes or no
questions about the primary-problem substance. Nine
out of 11 questions are used to determine severity of
the addiction, with a maximum score of 9. Finally,
section Q2 the Depression, Anxiety and Stress Scale
(DASS-21) [42,43], is a self-report questionnaire that
measures symptoms of depression, anxiety and stress
by answering 21 questions on a four-point scale
(anchored with 0 = ‘Did not apply to me at all’ and 3 =
‘Applied to me very much, or most of the time’), and is
used to identify psychiatric comorbidity. The sum of all
21 questions multiplied by two, gives the DASS-21 total
score, with a maximum of 126.
Montreal cognitive assessment. The MoCA [39] con-
sists of 13 items measuring seven cognitive domains:
executive functioning; visuospatial abilities; attention,
concentration and working memory (referred to as
‘attention’ from now on); language; abstract reasoning;
memory; and orientation. The authorised Dutch trans-
lation of MoCA version 7.1 was used in this study (see
www.mocatest.org). Administration of the MoCA takes
approximately 15 min and scoring can mostly be done
during administration. A total score is calculated by
summing scores on all items, with a maximum of
30 points, where higher scores represent better cognitive
performance. An adjustment for level of education is
applied in which participants with a low level of educa-
tion are awarded two extra points and participants with
an average level of education are awarded one extra
point, maintaining the maximum score of 30 [44]. In
addiction care, an optimal cut-off score of 24 was found
to be predictive of substance-induced cognitive impair-
ments, with a sensitivity of 0.56 and a speciﬁcity of
0.62, using an extensive neuropsychological assessment
as gold standard [45].
Procedure
As part of the intake procedure, the MATE 2.1 was
administered to each participant seeking treatment.
After the intake, participants were informed about the
study. Written informed consent was required for par-
ticipation and for using information of the administered
MATE 2.1. MoCA version 7.1 was administered by
professionals (e.g. psychologists, social psychiatric
nurses, social workers) immediately or in the following
appointment. All professionals were trained in MoCA
administration and scoring by the psychologist coordi-
nating this study in accordance with the formal instruc-
tions and based on experience of the psychologist for
ambiguities that are not clariﬁed in these instructions.
Patients provided demographic information, such as
sex, age, level of education, marital status and employ-
ment. Also, self-reported use of the primary-problem
substance in the week before MoCA administration, or
abstinence duration (if >7 days) was recorded.
Analyses
For descriptive purposes, differences in patient charac-
teristics between subgroups and between the four
addiction treatment centres were explored using χ2
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tests and univariate analyses of variance (ANOVA).
Second, the prevalence of cognitive impairments was
calculated for the total sample and per primary-
problem substance. Third, MoCA total and domain
scores for the total sample and differences between
primary-problem substances were analysed using uni-
variate and multivariate ANOVAs, respectively.
Finally, the effects of age, years of regular use, absti-
nence duration in days, severity of dependence and/or
abuse (Section Alcohol & Drugs of the Composite
International Diagnostic Interview), and depression,
anxiety and stress (DASS-21) on MoCA total score
were examined by Pearson correlations; abstinence
(<7 days/7–41 days/≥42 days) [46] with a univariate
ANOVA; and the effect of polysubstance use (yes/no)
on the MoCA total score was examined with an
independent t test. Hochberg’s GT2 (unequal
sample sizes) or Games–Howell post-hoc tests (non-
homogeneous population variances) were used as post-
hoc analyses in all ANOVA. Alpha was set at 0.05 for
all analyses and all data were computed and analysed
using IBM SPSS version 25.0.
Results
Patient characteristics
A total of 656 patients was included (77% male). The
mean age was 40 years (SD = 13.9). The most prevalent
primary-problem substance was alcohol (60%), followed
by cannabis (19%), stimulants (15%) and opioids (4.%).
Only 6 patients primarily used sedatives and another 10
used gamma-hydroxybutyrate as the primary-problem
substance (2%). Due to these small numbers, these
patients were only included in analyses regarding the
total sample. Patient characteristics differed signiﬁcantly
between patients with different primary-problem sub-
stances, except for the MATE 2.1 subscales depression
and anxiety (Table A1 in Appendix). Between patients
from all four health-care centres, there were signiﬁcant
differences for primary-problem substance, marital sta-
tus, abstinence, depression, stress and DASS-21 total
score.
Cognitive impairments
In the current sample, 206 patients (31%) performed
below the MoCA cut-off score of 24. Per primary-
problem substance, the prevalence was 34% for
alcohol, 21% for cannabis, 27% for stimulants and
38% for opioids. Post-hoc tests revealed that only
patients using alcohol performed signiﬁcantly worse on
the MoCA total score than those using cannabis
(Table 1). However, taking into consideration the sen-
sitivity and speciﬁcity of the MoCA in addiction care
[45], a rather high proportion of patients with actual
cognitive impairments may remain undetected, while
at the same time cognitively intact patients are classi-
ﬁed as being cognitively impaired by the MoCA.
Differences between primary-problem substances for
cognitive domains
Of all the possible differences that could be found
between the primary-problem substances in performance
on the MoCA domain scores, only three were signiﬁcant.
Patients using alcohol performed signiﬁcantly worse on
memory than those using cannabis [M diff = 0.44
(SD = 0.14), P = 0.01]. Patients using opioids per-
formed signiﬁcantly worse on visuospatial abilities than
those using cannabis [M diff = 0.64 (SD = 0.20),
P = 0.01] and those using stimulants [M diff = 0.61
(SD = 0.21), P = 0.02]. Additionally, patients using opi-
oids performed worse on memory than those using can-
nabis, which was marginally signiﬁcant [M diff = 0.96
(SD = 0.35), P = 0.05]. A signiﬁcant main effect was
found for executive functioning, with no signiﬁcant post-
hoc differences between substances.
Factors related to cognitive performance
In the total sample, the MoCA total score was negatively
correlated with age (r = −0.28, P < 0.01), with a shared
variance of only 9%. None of the other investigated fac-
tors (i.e. years of regular use, abstinence duration, sever-
ity of dependence and/or abuse, depression, anxiety and
stress) were signiﬁcantly correlated with the MoCA total
score. Abstinence and polysubstance use were also not
related to the MoCA total score (all P values > 0.05).
Since age was signiﬁcantly correlated with MoCA total
score in the total sample and there was a signiﬁcant dif-
ference in mean age between substances, the correlation
between MoCA total score and age was calculated per
primary-problem substance. For alcohol age was nega-
tively correlated with MoCA total score (P = −0.33,
P < 0.01), for cannabis this negative correlation was mar-
ginally signiﬁcant (P = −0.15, P = 0.05), for stimulants
age was positively correlated with MoCA total score
(P = 0.17, P = 0.04), and the correlation between age
and MoCA total score for opioids was negative but not
signiﬁcant (r = −0.20, P = 0.17).
Discussion
To our knowledge this is the ﬁrst study in addiction
care in which a large and heterogeneous group of
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patients with SUD are assessed on cognitive impair-
ments. The current study found a prevalence of cogni-
tive impairments of 31% in the total sample, ranging
from 21% for cannabis to 39% for opioids. Patients
using alcohol had a signiﬁcantly lower MoCA total
score than those using cannabis and it was found that
in the total sample younger patients scored signiﬁ-
cantly higher than older patients. Years of regular use,
abstinence (duration), severity of dependence and/or
abuse, polysubstance use, depression, anxiety and
stress were not related to MoCA outcomes.
Previous research shows a prevalence of cognitive
impairments in patients with SUD ranging from 30%
to 80% [3]. The prevalence in our study falls at the
bottom of this range, yet is still remarkable as cognitive
impairments are found to affect treatment outcomes.
Differences between primary-problem substances on
MoCA performance were not as profound as expected.
Patients using alcohol had lower outcomes than those
using cannabis, both on the MoCA total score and on
the domain memory, and patients using opioids had
lower outcomes on visuospatial abilities in comparison
to those using cannabis and stimulants. The lack of
signiﬁcant differences could be inﬂuenced by the high
percentage of polysubstance users in our sample and
the relatively small number of patients using opioids
(see Table A1). There was a signiﬁcant difference in
age between substance types, and age was found to
have an effect on MoCA performance in this study.
The ﬁnding that age is negatively correlated to MoCA
scores is in line with ﬁndings in a sample of patients
with AUD aged >18 [47] and also in a sample of
healthy controls aged 25–91 [48]. It is, however, strik-
ing that the directionality of the correlation between
age and MoCA total score was different for stimulants
than for the other substances. This may be a conse-
quence of the primarily enhancing effects of stimulant
intoxication at low doses [19,20], although abstinence
was no signiﬁcant factor on MoCA performance in the
total sample. Substance type and age are thus factors
that should be taken into account when interpreting
the MoCA total score.
SUD patients may experience more psychological
complaints than healthy people, and they are not
always abstinent at intake. In our sample, none of the
variables (abstinence, abstinence duration, polysub-
stance use, years of regular use, severity of dependence
and/or abuse, depression, anxiety and stress) were
related to MoCA outcome. The lack of relations
between MoCA total score and depression, anxiety
and stress is in line with recent ﬁndings in a sample of
polysubstance users where the MoCA total score was
not related to results on a (psychiatric) symptom
checklist [49]. As for abstinence and abstinence dura-
tion, our ﬁndings are not in line with the literature, as
a review by Walvoort et al. [46] points to a minimum
period of 6 weeks abstinence before an extensive
(neuro)psychological assessment can be carried out
validly.
In clinical practice, cognitive impairments often
remain undetected at the start of or during treatment.
Early detection of cognitive impairments is essential to
increase the chance of a favourable outcome of treat-
ments and the MoCA is a relatively quick and easy tool
to assess cognitive functioning at intake. When cogni-
tive impairments are indeed present, adequate inter-
ventions, such as cognitive training [50] or errorless
learning [51] may help to increase treatment compli-
ance, self-efﬁcacy and cognitive performance. As our
results show, screenings for cognitive impairment can
be validly interpreted in every patient applying for
addiction treatment, independent of possibly relevant
characteristics. When interpreting ﬁndings obtained
with the MoCA one should, however, take into
Table 1. Mean (SD) Montreal cognitive assessment (MoCA) domain and total scores for the total sample and per primary-problem
substance. Post-hoc gives a description of signiﬁcant differencesa
Cognitive domain (score range)
Total
(n = 656)
Alcohol (A)
(n = 391)
Cannabis (C)
(n = 123)
Stimulants (S)
(n = 100)
Opioids (O)
(n = 26) P value Post-hoc
Executive functioning (0–2) 1.31 (0.67) 1.27 (0.68) 1.45 (0.66) 1.34 (0.66) 1.12 (0.77) 0.04
Visuospatial abilities (0–4) 2.77 (0.94) 2.73 (0.95) 2.91 (0.90) 2.88 (0.88) 2.27 (1.00) <0.01 C, S > O
Attention (0–6) 5.40 (0.97) 5.44 (0.95) 5.42 (0.92) 5.40 (0.90) 5.23 (1.31) 0.74
Language (0–5) 4.46 (0.72) 4.44 (0.76) 4.48 (0.67) 4.51 (0.70) 4.58 (0.64) 0.68
Abstract reasoning (0–2) 1.52 (0.63) 1.51 (0.64) 1.58 (0.60) 1.51 (0.58) 1.65 (0.63) 0.55
Memory (0–5) 3.30 (1.49) 3.21 (1.56) 3.65 (1.24) 3.33 (1.33) 2.69 (1.72) 0.01 A < C
Orientation (0–6) 5.75 (0.61) 5.76 (0.62) 5.74 (0.54) 5.79 (0.54) 5.77 (0.65) 0.94
MoCA total (0−30) 25.52 (3.12) 25.30 (3.23) 26.33 (2.69) 25.86 (2.72) 24.69 (3.88) <0.01 A < C
n (%) scoring below cut-off 206 (31) 134 (34) 26 (21) 27 (27) 10 (38) 0.03 A > C
aPatients with sedatives or gamma-hydroxybutyrate as the primary-problem substance are only included in the total sample and
not separately described.
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account that older adults with SUD may perform
lower than younger adults with SUD (except for stim-
ulants, were the opposite effect of age was found).
Some strengths to our study are in the design, which
was kept as close to clinical practice as possible, by
only adding a MoCA assessment to the intake proce-
dure as usual. Also, patients were only excluded if
administration of the MoCA was impossible. Conse-
quently, a large number of patients using different sub-
stances, whether or not abstinent and with a variety of
psychological complaints, could be included. There-
fore, results are representative of clinical practice.
There are some limitations to the current study. First,
it was impossible to perfectly balance the number of
patients for each primary-problem substance. Users of
cocaine, amphetamines and ecstasy were therefore
combined into ‘stimulants’ and the relatively small
number of patients using opioids lowered the power
of the analyses that included this group. The small
number of patients using sedatives and gamma-
hydroxybutyrate were not included in the compari-
sons making it impossible to conclude about
consequences on cognitive functioning for these
substances. Finally, the rather low sensitivity and
speciﬁcity of the MoCA for use in addiction care [45]
may have inﬂuenced our results and therefore the
actual prevalence of cognitive impairments may well
be different than that currently found.
In conclusion, a prevalence of 31% for cognitive
impairments was found in addiction care and, there-
fore, detection of cognitive impairments at an early
stage of treatment is important to determine the course
of treatment and maximise treatment outcome. Signiﬁ-
cant differences in MoCA performance were only
found between patients using alcohol and cannabis, but
not between other substances. Because of the under-
representation of patients using opioids in our sample,
differences between this group and the other substance
groups cannot be excluded. More research is needed
on how to adjust for the effect of age on MoCA perfor-
mance in individuals without SUD. Finally, we empha-
sise the fact that the MoCA is not intended as a
diagnostic instrument and that a full neuropsychologi-
cal assessment is always preferred. We therefore recom-
mend to use the MoCA as a ﬁrst screen in the triage
for subsequent more expensive and time-consuming
(extensive neuropsychological) assessments.
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Appendix
Table A1 Patient characteristics in the total sample and per primary-problem substancea
Total
(n = 656)
Alcohol (A)
(n = 391)
Cannabis (C)
(n = 123)
Stimulants (S)
(n = 100)
Opioids (O)
(n = 26) P value Post-hoc
Mean age in years (SD) 40.4 (13.9) 46.6 (12.6) 28.9 (8.9) 30.2 (8.8) 43.0 (9.9) <0.01 A,O>C,S
Sex (%) <0.01
Male 505 (77) 285 (73) 105 (85) 80 (80) 25 (96)
Female 151 (33) 106 (27) 18 (15) 20 (20) 1 (4)
Health-care centre (%) <0.01
IrisZorg 178 (27) 102 (26) 32 (26) 21 (21) 21 (81)
Novadic-Kentron 166 (25) 96 (25) 30 (24) 29 (29) 3 (12)
Tactus 141 (22) 97 (25) 20 (16) 20 (20) 1 (4)
Vincent van Gogh 171 (26) 96 (25) 41 (33) 30 (30) 1 (4)
Level of education (%) <0.01
Low 126 (19) 64 (16) 30 (24) 18 (18) 11 (42)
Average 421 (64) 242 (62) 78 (63) 76 (76) 14 (54)
High 109 (17) 85 (23) 15 (12) 6 (6) 1 (4)
Employment (%) <0.01
Employed (full-/part-time) 253 (39) 148 (38) 47 (38) 44 (44) 8 (31)
Unemployed 229 (35) 112 (29) 51 (42) 45 (45) 14 (54)
Incapacitated 139 (21) 96 (25) 25 (20) 11 (11) 4 (15)
Retired 35 (5) 35 (9) 0 (0) 0 (0) 0 (0)
Marital status (%) <0.01
Single 269 (41) 118 (30) 76 (62) 54 (54) 14 (54)
With partner 256 (39) 168 (43) 37 (30) 35 (35) 7 (27)
Separated/divorced 119 (18) 95 (24) 10 (8) 10 (10) 4 (15)
Widowed 12 (2) 10 (3) 0 (0) 1 (1) 1 (4)
Years of regular useb (n = 381) (n = 229) (n = 65) (n = 60) (n = 17)
Mean no. years (SD) 14.01 (11.54) 15.78 (12.93) 13.26 (8.33) 8.90 (6.43) 14.29 (12.25) <0.01 A,C>S
Polysubstance useb (%) (n = 432) (n = 247) (n = 71) (n = 76) (n = 23) <0.01
No 133 (31) 125 (51) 5 (7) 1 (1) 0 (0)
Yes 299 (69) 122 (49) 66 (93) 75 (99) 23 (100)
Abstinencec (%) <0.01
No (<7 days) 474 (72) 275 (70) 107 (87) 56 (56) 25 (96)
Yes (7–41 days) 128 (20) 83 (21) 8 (7) 35 (35) 0 (0)
Yes (≥42 days) 54 (8) 33 (8) 8 (7) 9 (9) 1 (4)
Abstinence durationb (n = 182) (n = 116) (n = 16) (n = 44) (n = 1)
Mean no. days (SD) 42.85 (57.50) 36.84 (42.80) 66.44 (88.52) 46.00 (68.84) 270.00 (−) <0.01
History of treatmentb (%) (n = 650) (n = 387) (n = 122) (n = 100) (n = 25) <0.01
No 357 (55) 210 (54) 86 (71) 48 (48) 5 (20)
Yes 293 (45) 177 (46) 36 (30) 52 (52) 20 (80)
CIDI-SADb (SD) (n = 470) (n = 287) (n = 81) (n = 69) (n = 20)
Dependence 4.79 (1.75) 4.71 (1.77) 4.68 (1.77) 5.42 (1.34) 4.30 (2.03) <0.01 A,C<S
Abuse 2.09 (1.11) 2.05 (1.11) 1.94 (1.04) 2.48 (1.02) 1.80 (1.36) <0.01 A,C<S
Severity 6.11 (2.21) 6.00 (2.20) 6.00 (2.34) 6.99 (1.74) 5.40 (2.80) <0.01 A,C<S
DASS-21b (SD) (n = 581) (n = 353) (n = 107) (n = 83) (n = 24)
Depression 13.89 (11.29) 13.47 (11.40) 15.87 (10.89) 14.00 (11.50) 10.42 (10.04) 0.11
0.13Anxiety 9.52 (8.43) 8.96 (7.87) 11.03 (9.43) 9.78 (8.88) 8.25 (8.43)
Stress 15.61 (10.27) 14.14 (9.63) 18.92 (9.96) 18.07 (11.24) 12.08 (11.18) <0.01 A,O<C; A<S
DASS-21 total 39.05 (26.53) 36.57 (25.78) 45.81 (26.29) 42.10 (27.45) 30.75 (26.45) <0.01 A<C
aPost-hoc gives a description of signiﬁcant differences. Patients with sedatives or gamma-hydroxybutyrate as the primary-problem
substance are only included in the total sample and not separately described. bDue to missing data the n included is mentioned
separately. cAbstinence was only assessed for the primary-problem substance. CIDI-SAD, Section Alcohol & Drugs of the Com-
posite International Diagnostic Interview; DASS-21, Depression Anxiety Stress Scales.
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